Company intelligence / Profile preview

Suzhou Kaixi Pharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Suzhou Kaixi Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative ophthalmic therapies. The company leverages a proprietary lipid nanoparticle (LNP) drug delivery platform to create long-acting formulations of established and novel therapeutic agents. Its lead candidate, KX-012, is a small molecule LNP formulation designed for the treatment of neovascular age-related macular degeneration and other retinal vascular diseases. By focusing on advanced delivery systems, Suzhou Kaixi aims to reduce the frequency of intravitreal injections and improve patient compliance and outcomes in the ophthalmology space.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Suzhou Kaixi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Kaixi Pharmaceutical.

Explore the full profile